# EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

> **NCT03720873** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 90 (estimated)

## Conditions studied

- EGFR Gene Mutation

## Interventions

- **DRUG:** erlotinib or gefitinib or icotinib
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT03720873
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10
- **Primary completion:** 2021-06
- **Final completion:** 2022-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720873, "EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT03720873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*